• Inocras

  Participated · Series B · Aug 2026

  Inocras develops whole-genome sequencing and proprietary bioinformatics solutions to translate comprehensive genomic data into curated, clinically actionable insights. Its oncology offerings include CancerVision™ for comprehensive tumor profiling and MRDVision™ for molecular residual disease detection, with automated interpretation capabilities. The company operates a CLIA/CAP-certified laboratory and reports real-world clinical adoption across Asia, with its solutions used by more than 100 cancer institutions and in thousands of patient cases. Inocras has established a significant commercial presence in Hong Kong and supports approximately thirty hospitals in South Korea. The company has collaborated with researchers at the Broad Institute to analyze whole-genome data from The Cancer Genome Atlas, informing broader use of standardized whole-genome analysis. The recent fundraise brought total funding to approximately $100 million to support further commercial expansion, particularly into the United States.

• Nventric

  Participated · Equity · Jun 2026

  Enventric develops vascular medical devices for cerebral infarction treatment, with approved products including the EvoGlide distal access catheter and the ULTRIVA stent retriever. The company reported cumulative revenue of about 6 billion won over the past four years and a compound annual growth rate of 52.9% over that period. Enventric is accelerating R&D and expanding manufacturing capacity following recent regulatory approvals. It is pursuing global market entry and has begun formal IPO preparations on KOSDAQ, appointing Kiwoom Securities as its underwriter. The recent 34.5 billion won pre-IPO equity raise broadens its institutional investor base and includes follow-on participation from several existing investors. Management has stated the capital will be used to bolster R&D, scale manufacturing, and support the company’s listing and international expansion efforts.

• BreezeBio

  Participated · Series B · Feb 2026

  BreezeBio, formerly GenEdit, engineers polymer-based NanoGalaxy nanoparticles that deliver genetic payloads such as mRNA with cell-type precision across immune, cardiac, pulmonary and central nervous system tissues. The company has shifted from being solely a delivery-technology provider to building a therapeutic pipeline concentrated on autoimmune disease and oncology. Its lead candidate, BRZ-101, delivers autoantigen-encoding mRNA and tolerogenic co-factors to antigen-presenting cells to induce antigen-specific regulatory T cells and aims to restore immune tolerance in type 1 diabetes; the program is now entering IND-enabling studies after positive preclinical results in mice and non-human primates. BreezeBio is also extending NanoGalaxy with ligand conjugation to reach T cells and enable in vivo CAR-T therapies. Beyond internal programs, the firm maintains a multi-year collaboration and licensing agreement with Genentech that has already produced an initial milestone payment. The recent financing strengthens its balance sheet, allowing continued platform expansion and clinical advancement of its pipeline.

No current team members are available.